Curative effect of motherwort combined with ethinylestradiol-cyproterone acetate on dysfunctional uterine bleeding

Qiaoyun Tang, Xueyuan Chen
In: Expert Review of Hematology · 2024 · vol. 17(4-5) , pp. 165–171 · doi:10.1080/17474086.2024.2343878 · PMID:38613836 · W4394782661
article OA: closed CC0
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Combining motherwort with ethinylestradiol-cyproterone acetate for dysfunctional uterine bleeding improved treatment response rates and normalized uterine hemodynamics and sex hormone levels compared to ethinylestradiol-cyproterone acetate alone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text ⓘ

This randomized study evaluated whether adding motherwort to ethinylestradiol-cyproterone acetate (EE/CPA) improves outcomes in 68 patients with dysfunctional uterine bleeding (DUB), comparing a single-medication group (EE/CPA) versus a combination group (motherwort plus EE/CPA). After 3 months, the combination group showed a significantly higher total response rate and greater changes in uterine hemodynamic measures (including lower uterine volume, endometrial thickness, and resistance index, with higher pulsatility index and uterine artery blood flow) along with lower sex hormone levels and coagulation/blood-count indices compared with the single-medication group. The authors’ stated limitations are not specified in the excerpt provided, though the results are limited to short-term 3-month outcomes and the study’s design details beyond group assignment are not described here. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: This study aimed to investigate the curative effect of motherwort combined with ethinylestradiol-cyproterone acetate (EE/CPA) on dysfunctional uterine bleeding (DUB). METHODS: Atotal of 68 patients with DUB were divided into a single medication group (treated with EE/CPA) and a combination medication group(treated with motherwort and EE/CPA). The clinical efficacy, uterine hemodynamic parameters, sex hormone levels, coagulation index levels, blood routine test levels, and adverse reactions of patients were evaluated. RESULTS: After three months of treatment, total treatment response rate of the combination medication group was significantly higher than that of the single medication group. Decreased uterine volume, endometrial thickness and resistance index (RI), increased pulsatility index(PI), average flow rate, and uterine artery blood flow, as well asreduced follicle-stimulating hormone (FSH), luteinizing hormone (LH),estradiol (E2), progesterone (P), activated partial thromboplastin time (aPTT), prothrombin time (PT), fibrinogen (FIB), thrombin time(TT), platelet count (PLT), red blood cell (RBC), and hemoglobin (Hb)levels were witnessed in patients of the two groups. In thecombination medication group, there exhibited reduced uterine volume, endometrial thickness and RI, elevated PI, average flow rate, and uterine artery blood flow, reduced P, E2, FSH, LH, aPTT, PT, FIB, TT,PLT, RBC, and Hb levels in comparison to the single medication group. CONCLUSION: The combination of motherwort and EE/CPA is clinically effective in the treatment of DUB.
Full text 2,688 characters · extracted from oa-doi-fallback · 4 sections · click to expand

Abstract

Objective This study aimed to investigate the curative effect of motherwort combined with ethinylestradiol-cyproterone acetate (EE/CPA) on dysfunctional uterine bleeding (DUB).

Methods

Atotal of 68 patients with DUB were divided into a single medication group (treated with EE/CPA) and a combination medication group(treated with motherwort and EE/CPA). The clinical efficacy, uterine hemodynamic parameters, sex hormone levels, coagulation index levels, blood routine test levels, and adverse reactions of patients were evaluated.

Results

After three months of treatment, total treatment response rate of the combination medication group was significantly higher than that of the single medication group. Decreased uterine volume, endometrial thickness and resistance index (RI), increased pulsatility index(PI), average flow rate, and uterine artery blood flow, as well asreduced follicle-stimulating hormone (FSH), luteinizing hormone (LH),estradiol (E2), progesterone (P), activated partial thromboplastin time (aPTT), prothrombin time (PT), fibrinogen (FIB), thrombin time(TT), platelet count (PLT), red blood cell (RBC), and hemoglobin (Hb)levels were witnessed in patients of the two groups. In thecombination medication group, there exhibited reduced uterine volume, endometrial thickness and RI, elevated PI, average flow rate, and uterine artery blood flow, reduced P, E2, FSH, LH, aPTT, PT, FIB, TT,PLT, RBC, and Hb levels in comparison to the single medication group.

Conclusion

The combination of motherwort and EE/CPA is clinically effective in the treatment of DUB. Declaration of interest The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. Reviewer disclosures Peer reviewers on this manuscript have no relevant financial or other relationships to disclose. Author contributions Q Tang contributed to the study design. X Chen contributed to the manuscript editing. Q Tang and X Chen contributed to the experimental studies and data analysis. All authors have read and have approved the final manuscript. Ethical approval The work has been approved by the ethics committee of the Traditional Chinese Medical Hospital of Yongkang (approval number: 20200125) with written informed consent obtained from all participants. Supplementary material Supplemental data for this article can be accessed online at https://doi.org/10.1080/17474086.2024.2343878

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

References (29)

Source provenance

openalex
last seen: 2026-05-10T11:02:14.326788+00:00
License: CC0 · commercial use OK